Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver

International Journal of Pharmaceutics

Volumn 475, Issue 1, 2014, Pages 597-604

  Vivian, Diana ^a   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Bile acid; Floxuridine; Na+ taurocholate cotransporting; polypeptide (NTCP, SLC10A1); Prodrug; Targeted drug delivery

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; FLOXURIDINE; FLOXURIDINE 3 0 GLUTAMIC ACID CHENODEOXYCHOLIC ACID; FLOXURIDINE 5' GLUTAMIC ACID CHENODEOXYCHOLIC ACID; POLYPEPTIDE; PRODRUG; SODIUM; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; COTRANSPORTER; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CELL MEMBRANE; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE TECHNIQUE; CHEMISTRY; LIQUID CHROMATOGRAPHY; METABOLISM; TANDEM MASS SPECTROMETRY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL CULTURE TECHNIQUES; CHENODEOXYCHOLIC ACID; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FLOXURIDINE; HUMANS; LIVER; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PRODRUGS; RATS; SYMPORTERS; TANDEM MASS SPECTROMETRY; TAUROCHOLIC ACID;

EID: 84907943470     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.09.014     Document Type: Article

References (42)

1. A. Balakrishnan, and J.E. Polli Deleterious effect of high transporter expression in the estimation of transporter kinetics AAPS J. 7 2005 R6224
2. A. Balakrishnan, and J.E. Polli Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target Mol. Pharm. 3 2006 223 230
3. A. Balakrishnan, S.A. Wring, A. Coop, and J.E. Polli Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter Mol. Pharm. 3 2006 282 292
4. A. Balakrishnan, N. Hussainzada, P. Gonzalez, M. Bermejo, P.W. Swaan, and J.E. Polli Bias in estimation of transporter kinetic parameters from overexpression systems: interplay of transporter expression level and substrate affinity J. Pharmacol. Exp. Ther. 320 2007 133 144
5. G.D. Birnie, H. Kroeger, and C. Heidelberger Studies of fluorinated pyrimidines: XVIII The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase Biochemistry 2 1963 566 572
6. P.A. Dawson Role of the intestinal bile acid transporters in bile acid and drug disposition Handb. Exp. Pharmacol. 201 2011 169 203
7. P. de Miranda, and M.R. Blum Pharmacokinetics of acyclovir after intravenous and oral administration J. Antimicrob. Chemother. 12 1983 29 37
8. R.J. Fraile, L.H. Baker, T.R. Buroker, J. Horwitz, and V.K. Vaitkevicius Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion Cancer Res. 40 1980 2223 2228
9. A. Geier, M. Wagner, C.G. Dietrich, and M. Trauner Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration Biochim. Biophys. Acta. 1773 2007 283 308
10. J.L. Grem 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development Invest. New Drugs 18 2000 299 313
11. D.C. Hohn, R.J. Stagg, M.A. Friedman, J.F. Hannigan Jr., A. Rayner, R.J. Ignoffo, P. Acord, and B.J. Lewis A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial J. Clin. Oncol. 7 1989 1646 1654
12. M.A. Jacobson Valaciclovir (BW256U87): the l-valyl ester of acyclovir J. Med. Virol. 1993 150 153
13. P.G. Johnston, H.J. Lenz, C.G. Leichman, K.D. Danenberg, C.J. Allegra, P.V. Danenberg, and L. Leichman Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res. 55 1995 1407 1412
14. T. Kawaguchi, M. Saito, Y. Suzuki, N. Nambu, and T. Nagai Specificity of esterases and structure of prodrug esters II. Hydrolytic regeneration behavior of 5-fluoro-2′-deoxyuridine (FUdR) from 3′,5′-diesters of FUdR with rat tissue homogenates and plasma in relation to their antitumor activity Chem. Pharm. Bull. (Tokyo) 33 1985 1652 1659
15. N. Kemeny, J.A. Conti, A. Cohen, P. Campana, Y. Huang, W.J. Shi, J. Botet, S. Pulliam, and J.R. Bertino Phase II. Study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma J. Clin. Oncol. 12 1994 2288 2295
16. V. Kolhatkar, and J.E. Polli Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups Eur. J. Pharm. Sci. 46 2012 86 99
17. G.A. Kullak-Ublick, J. Glasa, C. Boker, M. Oswald, U. Grutzner, B. Hagenbuch, B. Stieger, P.J. Meier, U. Beuers, W. Kramer, G. Wess, and G. Paumgartner Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas Gastroenterology 113 1997 1295 1305
18. G.A. Kullak-Ublick, B. Stieger, and P.J. Meier Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology. 126 2004 322 342
19. C.P. Landowski, B.S. Vig, X. Song, and G.L. Amidon Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs Mol. Cancer Ther. 4 2005 659 667
20. C.P. Landowski, X. Song, P.L. Lorenzi, J.M. Hilfinger, and G.L. Amidon Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism Pharm. Res. 22 2005 1510 1518
21. M. Leonhardt, M. Keiser, S. Oswald, J. Kühn, J. Jia, M. Grube, H.K. Kroemer, W. Siegmund, and W. Weitschies Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters Drug Metab. Dispos. 38 2010 1024 1028
22. R. Metzger, K. Danenberg, C.G. Leichman, D. Salonga, E.L. Schwartz, S. Wadler, H.J. Lenz, S. Groshen, L. Leichman, and P.V. Danenberg High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil Clin. Cancer Res. 4 1998 2371 2376
23. Y. Nishizawa, and J.E. Casida 3′,5′-diesters of 5-fluoro-2′-deoxyuridine: synthesis and biological activity Biochem. Pharmacol. 14 1965 1605 1619
24. S. Qian, J.B. Wu, X.C. Wu, J. Li, and Y. Wu Synthesis and characterization of new liver targeting 5-fluorouracil-cholic acid conjugates Arch. Pharm. (Weinheim) 342 2009 513 520
25. R. Rais, P.M. Gonzalez, X. Zheng, S.A. Wring, and J.E. Polli Method to screen substrates of apical sodium-dependent bile acid transporter AAPS J. 10 2008 596 605
26. Q. Ren, C.J. Van Groeningen, A. Hardcastle, G.W. Aherne, F. Geoffroy, C.J. Allegra, P.G. Johnston, and J.L. Grem Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells Oncol. Res. 9 1997 77 88
27. G. Roos, and U. Stenram Incorporation of 5-fluorouracil into hepatoma and normal tissue RNA at protein depletion in the rat J. Surg. Oncol. 65 1997 155 158
28. M.G. Rose, M.P. Farrell, and J.C. Schmitz Thymidylate synthase: a critical target for cancer chemotherapy Clin. Colorectal Cancer 1 2002 220 229
29. P. Rougier, A. Laplanche, M. Huguier, J.M. Hay, J.M. Ollivier, J. Escat, R. Salmon, M. Julien, J.C. Roullet Audy, D. Gallot, J.L. Gouzi, J.L. Pailler, D. Elisa, F. Lacaine, S. Roos, N. Rotman, M. Luboinski, and P. Lasser Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial J. Clin. Oncol. 10 1992 1112 1118
30. P. Rougier, A. Laplanche, M. Huguier, J.M. Hay, J.M. Ollivier, J. Escat, R. Salmon, M. Julien, J.C. Roullet Audy, and D. Gallot Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial J. Clin. Oncol. 10 1992 1112 1118
31. T.H. Senanayake, G. Warren, and S.V. Vinogradov Novel anticancer polymeric conjugates of activated nucleoside analogues Bioconjug. Chem. 22 2011 1983 1993
32. S.C. Tobias, and R.F. Borch Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs J. Med. Chem. 44 2001 4475 4480
33. S. Tolle-Sander, K.A. Lentz, D.Y. Maeda, A. Coop, and J.E. Polli Increased acyclovir oral bioavailability via a bile acid conjugate Mol. Pharm. 1 2004 40 48
34. D.R. Urbach, D.M. Herron, Y.S. Khajanchee, L.L. Swanström, and P.D. Hansen Laparoscopic hepatic artery infusion pump placement Arch. Surg. 136 2001 700 704
35. J.A. van Laar, Y.M. Rustum, S.P. Ackland, C.J. van Groeningen, and G.J. Peters Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer Eur. J. Cancer 34 1998 296 306
36. M. Vertzoni, H. Archontaki, and C. Reppas Determination of intralumenal individual bile acids by HPLC with charged aerosol detection J. Lipid Res. 49 2008 2690 2695
37. J.A. van Laar, Y.M. Rustum, S.P. Ackland, C.J. van Groeningen, and G.J. Peters Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer Eur. J. Cancer. 34 1998 296 306
38. S.A. Van Der Heyden, M.S. Highley, E.A. De Bruijn, U.R. Tjaden, H.J. Reeuwijk, H. Van Slooten, A.T. Van Oosterom, and R.A. Maes Pharmacokinetics and bioavailability of oral 5′-deoxy-5-fluorouridine in cancer patients Br. J. Clin. Pharmacol. 47 1999 351 356
39. B.S. Vig, P.J. Lorenzi, S. Mittal, C.P. Landowski, H.C. Shin, H.I. Mosberg, J.M. Hilfinger, and G.L. Amidon Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis Pharm. Res. 20 2003 1381 1388
40. D. Vivian, and J.E. Polli Mechanistic interpretation of conventional Michaelis-Menten parameters in a transporter system Eur. J. Pharm. Sci. 2014 10.1016/j.ejps.2014.08.007
41. Y. Wei, Y. Yan, D. Pei, and B. Gong A photoactivated prodrug Bioorg. Med. Chem. Lett. 8 1998 2419 2422
42. i values against solute carrier transporters Eur. J. Pharm. Sci. 41 2010 43 52